Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: A case-control study

BJU International

Volumn 104, Issue 5, 2009, Pages 651-656

  Grosse, Joachim ^a   Kramer, Guus ^b   Jakse, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b BG UNFALLKLINIK MURNAU   (Germany)

Author keywords

Botulinum A toxin; Clean intermittent catheterization; Detrusor injections; Neurogenic detrusor overactivity; Spinal cord injury; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLADDER; BLADDER COMPLIANCE; CASE CONTROL STUDY; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTOMETRY; DEMOGRAPHY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPOASTHENIA; INJECTION; MALE; OBSERVATIONAL STUDY; OPEN STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; REGRESSION ANALYSIS; STUDENT T TEST;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEUROMUSCULAR AGENTS; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY CATHETERIZATION; URINARY INCONTINENCE; YOUNG ADULT;

EID: 68849102594     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08466.x     Document Type: Article

References (19)

1. Wyndaele JJ, Castro D, Madersbacher H et al. Neurologic urinary and faecal incontinence. In Abrams P, Cardozo L, Khoury S, Wein A, Incontinence Management. Vol. II. Plymouth : Health Publication Ltd, 2005 : 1059 162
2. Stöhrer M, Schurch B, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: a new alternative to medical and surgical procedures? Neurourol Urodyn 1999 18 : 401 2
3. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary Results. J Urol 2000 164 : 692 7
4. Riccabona M, Koen M, Schindler M et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004 171 : 845 8
5. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005 47 : 653 9
6. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006 68 : 1193 7
7. Akbar M, Abel R, Seyler TM et al. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 2007 100 : 639 45
8. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type a injections yield valuable Results? Clinical and urodynamic Results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007 52 : 1729 35
9. Del Popolo G, Filocamo MT, Li Marzi V et al. Neurogenic detrusor overactivity treated with English botulinum toxin A. 8-year experience at one single centre Eur Urol 2008 53 : 1013 20
10. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In Jankovic J, Hallet M, Therapy with Botulinum Toxin. New York : Marcel Dekker, 1994 : 3 13
11. Abrams P, Cardozo L, Fall M et al., Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78
12. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988 139 : 919 22
13. Frenkl TL, Rackley RR. Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin North Am 2005 32 : 89 99
14. Reitz A, Stöhrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004 45 : 510 5
15. Patki PS, Hamid R, Arumugam K, Shah PJ, Craggs M. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006 98 : 77 82
16. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006 97 : 1030 4
17. Schurch B, de Sèze M, Denys P et al., Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005 174 : 196 200
18. Bakheit AM, Thilmann AF, Ward AB et al. A randomized, double-blind, placebo-controlled dose ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000 31 : 2402 6
19. De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005 43 : 397 9